Literature DB >> 16474103

Slipping the barrier: how variants in CARD15 could alter permeability of the intestinal wall and population health.

S Schreiber1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16474103      PMCID： PMC1856076          DOI： 10.1136/gut.2005.076075

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  36 in total

1.  Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms.

Authors:  Matthias Bruewer; Andreas Luegering; Torsten Kucharzik; Charles A Parkos; James L Madara; Ann M Hopkins; Asma Nusrat
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

2.  CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells.

Authors:  Tadakazu Hisamatsu; Manabu Suzuki; Hans-Christian Reinecker; William J Nadeau; Beth A McCormick; Daniel K Podolsky
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

Review 3.  Intestinal epithelial cells and innate immunity in the intestine: is CARD15/Nod2 another player?

Authors:  Christian Jobin
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

4.  NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression.

Authors:  J Wehkamp; J Harder; M Weichenthal; M Schwab; E Schäffeler; M Schlee; K R Herrlinger; A Stallmach; F Noack; P Fritz; J M Schröder; C L Bevins; K Fellermann; E F Stange
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

5.  The NOD2 3020insC mutation and the risk of colorectal cancer.

Authors:  Grzegorz Kurzawski; Janina Suchy; Józef Kładny; Ewa Grabowska; Marek Mierzejewski; Anna Jakubowska; Tadeusz Debniak; Cezary Cybulski; Elsbieta Kowalska; Zbigniew Szych; Wenancjusz Domagała; Rodney J Scott; Jan Lubiński
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

6.  Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment.

Authors:  S Zeissig; C Bojarski; N Buergel; J Mankertz; M Zeitz; M Fromm; J D Schulzke
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

7.  Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection.

Authors:  Stephen E Girardin; Ivo G Boneca; Jérôme Viala; Mathias Chamaillard; Agnès Labigne; Gilles Thomas; Dana J Philpott; Philippe J Sansonetti
Journal:  J Biol Chem       Date:  2003-01-13       Impact factor: 5.157

8.  NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease.

Authors:  Mihai G Netea; Bart Jan Kullberg; Dirk J de Jong; Barbara Franke; Tom Sprong; Ton H J Naber; Joost P H Drenth; Jos W M Van der Meer
Journal:  Eur J Immunol       Date:  2004-07       Impact factor: 5.532

9.  Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition.

Authors:  Tsuyoshi Tanabe; Mathias Chamaillard; Yasunori Ogura; Li Zhu; Su Qiu; Junya Masumoto; Partho Ghosh; Anthony Moran; Martina M Predergast; Gerard Tromp; Charlene J Williams; Naohiro Inohara; Gabriel Núñez
Journal:  EMBO J       Date:  2004-03-25       Impact factor: 11.598

10.  Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives?

Authors:  Bjarni Thjodleifsson; Gudmundur Sigthorsson; Nick Cariglia; Inga Reynisdottir; Daniel F Gudbjartsson; Kristleifur Kristjansson; Jonathan B Meddings; Vilmundur Gudnason; Johan H Wandall; Leif Percival Andersen; Roy Sherwood; Matthias Kjeld; Einar Oddsson; Hallgrimur Gudjonsson; Ingvar Bjarnason
Journal:  Gastroenterology       Date:  2003-06       Impact factor: 22.682
View more
  1 in total

Review 1.  Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics.

Authors:  Luca Pastorelli; Carlo De Salvo; Joseph R Mercado; Maurizio Vecchi; Theresa T Pizarro
Journal:  Front Immunol       Date:  2013-09-17       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.